Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid ChoicesGlobeNewsWire • 02/12/26
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/27/26
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-PacificZacks Investment Research • 01/14/26
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific MarketsGlobeNewsWire • 01/13/26
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 RevenuesGlobeNewsWire • 01/08/26
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare ConferencesGlobeNewsWire • 01/07/26
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.PRNewsWire • 12/30/25
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back PainZacks Investment Research • 12/03/25
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu PharmaceuticalGlobeNewsWire • 11/26/25
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesGlobeNewsWire • 11/11/25
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the BusinessPRNewsWire • 11/11/25
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin GuidanceGlobeNewsWire • 11/06/25
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the KneeGlobeNewsWire • 11/05/25
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain ControlGlobeNewsWire • 11/04/25
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025GlobeNewsWire • 10/30/25